Navigation Links
First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals' GGTI-2418
Date:5/1/2009

BONITA SPRINGS, Fla., May 1 /PRNewswire/ -- Tigris Pharmaceuticals, Inc., a privately held drug development company, announced today that dosing has started in a Phase I clinical trial of GGTI-2418. GGTI-2418 is a synthetic peptidomimetic inhibitor of geranylgeranyltransferase I (GGTase I) that induces apoptosis by downregulating several pivotal oncogenic and tumor survival pathways.

The Phase I study is led by Dr. Peter O'Dwyer, Professor of Medicine at the University of Pennsylvania School of Medicine and Program Leader of the Experimental Therapeutics Program at the Abramson Cancer Center of the University of Pennsylvania, and by Dr. Gabriela Chiorean, Assistant Professor of Medicine at the Indiana University School of Medicine and a physician/researcher with the Indiana University Melvin and Bren Simon Cancer Center.

"This is the first geranylgeranyltransferase inhibitor to move to clinical phase studies," stated Edmundo Muniz, M.D., Ph.D., President and Chief Executive Officer of Tigris. "Initiation of this Phase I study of GGTI-2418 in these two top Phase I cancer research centers is a significant step in the development of this first-in-class molecule to treat cancer in many different tumor types."

"We are excited to participate in the first study of this novel agent," commented Dr. Chiorean. "The development of a molecule to inhibit the geranylgeranyltransferase pathway would be a significant advancement in cancer treatment."

The primary objective of the Company's Phase I trial with GGTI-2418 is to determine its safety, tolerability, and recommended Phase II dose. Patients with metastatic solid tumors for which standard treatments have failed, or for whom standard therapies are not available, will be evaluated. The number of patients to be enrolled will depend on the number of patient cohorts investigated until dose-limiting toxicity is reached.

Tigris in-licensed the exclusive worldwide rights to GGTI-2418 from Yale University and the University of South Florida. Said M. Sebti, Ph.D., Director of the Drug Discovery Program at the Moffitt Cancer Center and Andrew Hamilton, Ph.D., Professor of Chemistry at Yale University were the co-inventors of GGTI-2418.

About GGTI-2418

GGTI-2418 is a synthetic peptidomimetic inhibitor of GGTase I that appears to induce apoptosis by downregulating several pivotal oncogenic and tumor survival pathways. GGTase I catalyzes the lipid posttranslational modification which is required for the function of Rho GTPases (frequently found aberrantly activated in human cancer). GGTase I inhibitors block Rho function in cancer cells and induce a G1 phase cell cycle arrest by a mechanism involving induction of the CDK inhibitors p21waf and p27kip, CDK2 and CDK4 inhibition and hypophoshorylation of the tumor suppressor Rb. GGTase I inhibitors also induce apoptosis by a mechanism involving downregulation of the expression of survivin and suppression of the activation of PI3K/Akt.

About Tigris Pharmaceuticals, Inc.

Tigris Pharmaceuticals, Inc. is a privately held biopharmaceutical company that develops therapeutic technologies, using a translational research approach, for use in oncology and other areas of unmet medical need. Tigris' mission is to efficiently move its existing and future technologies through the various stages of clinical development in order to meet patients' needs for safe and effective treatments of human illnesses.

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of GGTI-2418, its potential advantages, its potential for use in treating cancer, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning GGTI-2418. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of GGTI-2418, our ability to finance our development of GGTI-2418, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.


'/>"/>
SOURCE Tigris Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... LOS ANGELES, Calif. (PRWEB) , ... April 27, ... ... Los Angeles office of Lewis Roca Rothgerber Christie LLP as an associate in ... and prosecuting U.S. and international electrical, mechanical and electromechanical patent applications. He has ...
(Date:4/26/2016)... ... 2016 , ... Heidelberg Instruments, a leader in design, development ... Volume Pattern Generator (VPG) line of lithography systems. The breakthrough VPG+ system is ... a solution for mid volume direct write lithography applications. It utilizes the ...
(Date:4/26/2016)... ... 26, 2016 , ... BioFactura, Inc ., a biopharmaceutical research and manufacturing ... Healthy investor interest drove significant oversubscription of the original $1.5M target. The funds ... the advanced preclinical stages. , Chief Executive Officer and President, Darryl Sampey ...
(Date:4/26/2016)... ... ... uBiome, the leading microbial genomics company, welcomes Neil Grimmer, Co-founder and Chairman ... co-founding Plum in 2007, Neil Grimmer was Vice President of Strategy and Innovation at ... of ideas, products, and brands, Grimmer has been at the forefront of launching more ...
Breaking Biology Technology:
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
(Date:3/18/2016)... March 18, 2016 --> ... Biometrics, ICT, Manned & Unmanned Vehicles, Physical infrastructure and Perimeter ... companies in the border security market and the continuing migration ... Europe has led visiongain to publish ... success. --> defence & security companies in ...
(Date:3/15/2016)... JERUSALEM , March 15, 2016 ... Jerusalem , the technology-transfer company of the Hebrew University, ... developer of remote sensing technology of various human biological ... funding, raising $2.0 million from private investors. ... technology, based on the detection of electromagnetic emissions from ...
Breaking Biology News(10 mins):